The etiology of Parkinson's disease with emphasis on the MPTP story

Neurology

Volumn 47, Issue 6 SUPPL. 3, 1996, Pages

  Langston, J William ^a  

^a PARKINSON S INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; AMINE OXIDASE (FLAVIN CONTAINING);

AGING; DOPAMINERGIC NERVE CELL; HUMAN; LEWY BODY; NERVE DEGENERATION; NERVE INJURY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR;

EID: 0029751103     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.47.6_suppl_3.153s     Document Type: Review

References (66)

1. Calne DB. Is idiopathic parkinsonism the consequence of an event or a process? Neurology 1994;44:5-10.
2. Langston JW, Ballard PA, Tetrud JW, Irwin I. Chronic parkinsonism in humans due to a product of meperidine analog synthesis. Science 1983;219:979-980.
3. Spencer PS, Butterfield PG. Environmental agents and Parkinson's disease. In: Ellenberg JH, Koller WC, Langston JW, eds. Etiology of Parkinson's disease. New York: Marcel Dekker, 1995:319-365.
4. Gibb WRG, Lees AJ. The significance of the Lewy body in the diagnosis of idiopathic Parkinson's disease. Neuropathol Appl Neurobiol 1989;15:27-44.
5. Forno LS. Pathological considerations in the etiology of Parkinson's disease. In: Ellenberg JH, Koller WC, Langston JW, eds. Etiology of Parkinson's disease. New York: Marcel Dekker, 1995:65-95.
6. Forno LS, Langston JW, DeLanney LE, Irwin I, Ricaurte GA. Locus ceruleus lesions and eosinophilic inclusions in MPTP-treated monkeys. Ann Neurol 1986;20:449-455.
7. Forno LS, DeLanney LE, Irwin I, Langston JW. Ultrastructure of eosinophilic inclusion bodies in the amygdalaparahippocampal region of aged squirrel monkeys treated with 1-methyl-4-phenyl-1,2,3,6-tetranydropyridine, a dopaminergic neurotoxin. Neurosci Lett 1995;184:44-47.
8. Gibb WRG, Esiri MM, Lees AJ. Clinical and pathologic features of diffuse cortical Lewy body disease (Lewy body dementia). Brain 1985;110:1131-1153.
9. Marsden CD. Neuromelanin and Parkinson's disease. J Neural Transm Suppl 1983;19:121-141.
10. Olanow CW. Oxidation reactions in Parkinson's disease. Neurology 1990;40(Suppl)3:32-37.
11. Götz ME, Kunig G, Riederer P, Youdim MBH. Oxidative stress: free radical production in neural degeneration. Pharmacol Ther 1994;63:37-122.
12. Tetrud JW, Langston JW. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science 1989; 245:519-522.
13. The Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1989;321:1364-1371.
14. Edwards RH. Neural degeneration and the transport of neurotransmitters. Ann Neurol 1993;34:638-645.
15. German DC, Manaye KF, Sonsalla PK, Brooks BA. Midbrain dopaminergic cell loss in Parkinson's disease and MPTP-induced parkinsonism: sparing of calbindin D286 containing cells. Ann NY Acad Sci 1992;648:42-62.
16. Yamada T, McGeer PL, Baimbridge KG, McGeer EG. Relative sparing in Parkinson's disease of substantia nigra dopamine neurons containing calbindin D28k. Brain Res 1991;526:303-307.
17. Iacopino A, Christakos S, German DC, Sonsalla PK, Altar CA. Calbindin D286 containing neurons in animal models of neurodegeneration: possible protection from excitotoxicity. Mol Brain Res 1992;13:251-261.
18. Hirsch EC, Mouatt A, Thomasset M, Javoy-Agid F, Agid Y, Graybiel AM. Expression of calbindin D28K-like immunoreactivity in catecholaminergic cell groups of the human midbrain: normal distribution and distribution in Parkinson's disease. Neurodegeneration 1992;1:83-93.
19. Gibb WRG. Melanin, tyrosine hydroxylase, calbindin and substance P in the human midbrain and substantia nigra in relation to nigrostriatal projections and differential neuronal susceptibility in Parkinson's disease. Brain Res 1992;581:283-291.
20. Gupta M, Felten DL, Ghetti B. Selective loss of monoaminergic neurons in weaver mutant mice: an immunocytochemical study. Brain Res 1987;402:379-382.
21. Gaspar P, Ben Jelloun N, Febvret A. Sparing of the dopaminergic neurons containing calbindin D286 and of the dopaminergic mesocortical projections in weaver mutant mice. Neuroscience 1994;61:293-305.
22. Pu C, Fisher JE, Cappon GD, Vorhees CV. The effects of amfonelic acid, a dopamine uptake inhibitor, on methamphetamine-induced dopaminergic terminal degeneration and astrocytic response in rat striatum. Brain Res 1994;649:217-224.
23. Seiden LS, Fischman MW, Schuster CR. Long-term methamphetamine-induced changes in brain catecholamines in tolerant rhesus monkeys. Drug Alcohol Depend 1975;1: 215-219.
24. Woolverton WL, Ricaurte GA, Forno LS, Seiden LS. Long-term effects of chronic methamphetamine administration in rhesus monkeys. Brain Res 1989;486:73-78.
25. Schuster CR, Fischman MW. Amphetamine toxicity: behavioral and neuropathological indexes. Fed Proc 1975;34:1845-1851.
26. Riederer P, Wuketich S. Time course of nigrostriatal degeneration in Parkinson's disease. J Neural Transm 1976;38:277-301.
27. Smith CAD, Gough AC, Leigh PN, et al. Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet 1992;339:1375-1377.
28. Armstrong M, Daly AK, Cholerton S, Bateman DN, Idle JR. Mutant debrisoquine genes in Parkinson's disease. Lancet 1992;339:1017-1018.
29. Chan P, Tanner CM, Langston JW. A new CYP2D6 mutation associated with Parkinson's disease in American Caucasians. Move Dis 1995;10:689.
30. Chan P, Tanner CM, Langston JW. Genetically determined differences in xenobiotic metabolism as a risk factor in Parkinson's disease. Fundam Appl Toxicol 1996;30(suppl):89.
31. Marttila RJ, Rinne UK. Epidemiology of Parkinson's disease: an overview. J Neural Transm 1981;51:135-148.
32. Calne DB, Langston JW. Aetiology of Parkinson's disease. Lancet 1983;2:1457-1459.
33. Ricaurte GA, Langston JW, Irwin I, DeLanney LE, Forno LS. The neurotoxic effect of MPTP on the dopaminergic cells of the substantia nigra in mice is age-related. Soc Neurosci Abstr 1985;11:631.
34. Ricaurte GA, Langston JW, DeLanney LE, Irwin I, Peroutka SJ, Forno LS. Fate of nigrostriatal neurons in young mature mice given 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: a neurochemical and morphological reassessment. Brain Res 1986;376:117-124.
35. Jarvis MF, Wagner GC. Age-dependent effects of MPTP. Neuropharmacology 1985;24:581-583.
36. Gupta M, Gupta BK, Thomas R, Bruemmer V, Sladek JR, Jr., Felten DL. Aged mice are more sensitive to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine than young adults. Neurosci Lett 1986;70:326-331.
37. Saitoh T, Niijima K, Mizuno Y. Long-term effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on striatal dopamine content in young and mature mice. J Neurol Sci 1987;77: 229-235.
38. Walsh SL, Wagner GC. Age-depedent effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): correlation with monoamine oxidase-B. Synapse 1989;3:308-314.
39. Irwin I, Finnegan KT, DeLanney LE, Di Monte DA, Langston JW. The relationships between aging, monoamine oxidase, striatal dopamine and the effects of MPTP in C57BL/6 mice: a critical reassessment. Brain Res 1992;572:224-231.
40. Irwin I, DeLanney LE, Langston JW. MPTP and aging: studies in the C57BL/6 mouse. In: Narabayashi H, Nagatsu T, Yanagisawa N, Mizuno Y, eds. Advances in neurology, vol 60, Parkinson's disease: from basic research to treatment. Proceedings of the 10th International Symposium on Parkinson's Disease. New York: Raven, 1993:197-206.
41. Irwin I, Langston JW. The fate of MPTP in mice and squirrel monkeys. In: Nagatsu T, Yoshida M, Kanazawa I, Ogawa N, eds. Brain and Parkinson's disease. Tokyo: Heibonsha, 1988: 71-79.
42. Finnegan KT, Irwin I, DeLanney LE, Langston JW. Age-dependent effects of the 2′-methyl analog of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: prevention by inhibitors of monoamine oxidase B. J Pharmacol Exp Ther 1995;273:716-720.
43. Heikkila RE, Kindt MV, Sonsalla PK, et al. Importance of monoamine oxidase A in the bioactivation of neurotoxic analogs of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci 1988;85:6172-6176.
44. Youngster SK, McKeown KA, Jin Y-Z, Ramsay RR, Heikkila RE, Singer TP. Oxidation of analogs of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by monoamine oxidases A and B and the inhibition of monoamine oxidases by the oxidation products. J Neurochem 1989;53:1837-1842.
45. Youngster SK, Duvoisin RC, Hess A, Sonsalla PK, Kindt MV, Heikkila RE, 1-Methyl-4-phenyl-(2′-methylphenyl)-1,2,3,6-tetrahydropyridine (2′CHS-MPTP) is a more potent dopamine neurotoxin than MPTP in mice. Eur J Pharmacol 1986;122: 283-287.
46. Langston JW, Forno LS, Rebert CS, Irwin I. Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the squirrel monkey. Brain Res 1984;292:390-394.
47. Rose SP, Nomoto M, Jackson EA, et al. Age-related effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment of common marmosets. Eur J Pharmacol 1993;230:177-185.
48. Irwin I, DeLanney LE, McNeill TH, et al. Aging and the nigrostriatal dopamine system: a non-human primate study. Neurodegeneration 1994;3:251-265.
49. Carlsson A, Winblad B. Influence of age and time interval between death and autopsy on dopamine and 3-methoxytyramine levels in human basal ganglia. J Neural Transm 1976;38:271-276.
50. Adolfsson R, Gottfries CG, Roos BE, Winblad B. Changes in brain catecholamines in patients with dementia of Alzheimer type. Br J Psychiatry 1979;135:216-223.
51. Kish SJ, Shannak K, Rajput AH, Deck JHN, Hornykiewicz O. Aging produces a specific pattern of striatal dopamine loss: implications for the etiology of idiopathic Parkinson's disease. J Neurochem 1992;58:642-648.
52. Osterburg HH, Donahue HG, Severson JA, Finch CE. Catecholamine levels and turnover during aging in brain regions of male C57BL/6J mice. Brain Res 1981;224:337-352.
53. Irwin I, DeLanney LE, Chan P, Sandy MS, Di Monte DA, Langston JW. Nigrostriatal monoamine. oxidase A and B in aging squirrel monkeys and C57B1/6 mice. Brain Res 1996 (submitted).
54. Schapira AHV. Mitochondrial complex I deficiency in Parkinson's disease. In: Narabayashi H, Nagatsu T, Yanagisawa N, Mizuno Y, eds. Advances in neurology, vol 60. New York: Raven, 1993:288-291.
55. Schapira AHV, Cooper JM, Dexter DT, Clark JB, Jenner P, Marsden CD. Mitochondrial complex I deficiency in Parkinson's disease. Ann Neurol 1989;26:122-123.
56. Hattori K, Tanaka M, Sugiyama S, et al. Age-dependent increase in deleted mitochondrial DNA in the human heart: possible contributory factor to presbycardia. Am Heart J 1991; 121:1735-1742.
57. Cortopassi GA, Arnheim N. Detection of a specific mitochondrial DNA deletion in tissues of older humans. Nucleic Acids Res 1990;18:6927-6933.
58. Nagley P, Mackay IR, Baumer A, et al. Mitochondrial DNA mutation associated with aging and degenerative disease. Ann NY Acad Sci 1992;673:92-102.
59. Di Monte DA, Sandy MS, DeLanney LE, et al. Age-dependent changes in mitochondrial energy production in striatum and cerebellum of the monkey brain. Neurodegeneration 1993;2: 93-99.
60. Bowling AC, Mutisya EM, Walker LC, Price DL, Cork LC, Beal MF. Age-dependent impairment of mitochondrial function in primate brain. J Neurochem 1993;60:1964-1967.
61. Brouillet E, Jenkins BG, Hyman BT, et al. Age-dependent vulnerability of the striatum to the mitochondrial toxin 3-nitropropionic acid. J Neurochem 1993;60:356-359.
62. Tomac A, Lindqvist E, Lin LFH, et al. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 1995;373:335-339.
63. Beck KD, Valverde J, Alexl T, et al. Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain. Nature 1995;373:339-341.
64. Manaye KF, Sonsalla PK, Barnett G, et al. 1-methyl-4-(2′-methylphenyl)-1,2,3,6-tetrahydropyridine (2′CH3-MPTP)-induced degeneration of mesostriatal dopaminergic neurons in the mouse: biochemical and neuroanatomical studies. Brain Res 1989;491:307-315.
65. German DC, Manaye KF, Smith WK, Woodward DJ, Saper CB. Midbrain dopaminergic cell loss in Parkinson's disease: computer visualization. Ann Neurol 1989;26:507-514.
66. Iacopino AM, Christakos S. Specific reduction of calcium-binding protein (28-kilodalton calbindin-D) gene expression in aging and neurodegenerative diseases. Proc Natl Acad Sci 1990;87:4078-4082.